Skip to content

Study · Systematic review · 2023

2 results

Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.

Ruan Z, Jiang Y, Shi H, Jia R, Ung COL, Hu H

Expert review of clinical pharmacology2 Feb 2023Cited by 7 (Europe PMC)

PMID36706368 (opens in a new tab)DOI10.1080/17512433.2023.2174099 (opens in a new tab)PepBankPUB-36706368
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of real-world studies in type 2 diabetes, once-weekly semaglutide was associated with improved glycemic control in patients naive to GLP-1 RA and in those previously treated with other GLP-1 RA.

    In plain wordsIn a review of real-world studies in type 2 diabetes, semaglutide was linked to better blood sugar control.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycemic control in real-world use
    Study

    n: not reported in source

    Comparator
    GLP-1 RA naive and GLP-1 RA experienced patients
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results of the review suggested that O.W. semaglutide therapy was associated with improving glycemic control and weight loss in both T2DM patients naïve to GLP-1RA and those previously treated with other GLP-1RA in routine clinical practice.
    1 context sentence
    Summary · context
    A comprehensive search of PubMed, Web of Science, Embase, and Scilit databases was performed from January 2017 to June 2022 to identify eligible real-world studies examining O.W. semaglutide in T2DM.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of real-world studies in type 2 diabetes, once-weekly semaglutide was associated with weight loss in patients naive to GLP-1 RA and in those previously treated with other GLP-1 RA.

    In plain wordsIn a review of real-world studies in type 2 diabetes, semaglutide was linked to weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in real-world use
    Study

    n: not reported in source

    Comparator
    GLP-1 RA naive and GLP-1 RA experienced patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results of the review suggested that O.W. semaglutide therapy was associated with improving glycemic control and weight loss in both T2DM patients naïve to GLP-1RA and those previously treated with other GLP-1RA in routine clinical practice.
    1 context sentence
    Summary · context
    A comprehensive search of PubMed, Web of Science, Embase, and Scilit databases was performed from January 2017 to June 2022 to identify eligible real-world studies examining O.W. semaglutide in T2DM.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.